GenMark Diagnostics

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Co-Diagnostics

Immunomedics

Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.

3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD

Invitae

Mike Cintolo is a leading growth stock expert and is the editor of Cabot Top Ten Trader.

2 Companies In The Fast-Growing Market For Molecular Diagnostics And Genetic Testing

As of late, it has definitely been a great time to be an investor in GenMark Diagnostics.

GenMark's Shares March Higher, Can It Continue?

Costco

Slack

ANGI Homeservices

Synaptics

We used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts.

Keep buying hot stocks like Slack and Costco, Wall Street's best-performing analysts say

Coronavirus test maker GenMark Diagnostics soared to a record high after second-quarter sales shattered expectations. GenMark has quadrupled in 2020 in the face of the Covid-19 pandemic.

Covid Report: Coronavirus Test Maker GenMark Diagnostics Jumps On Sales Beat

Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth

GenMark Diagnostics Provides Preliminary Financial and Operational Results for Second Quarter 2020

Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow

GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)

As of late, it has definitely been a great time to be an investor of GenMark Diagnostics

Will GenMark Diagnostics Continue to Surge Higher?

GenMark Diagnostics (GNMK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GenMark Diagnostics (GNMK) Upgraded to Strong Buy: Here's What You Should Know

Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections

GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health

GenMark Diagnostics has been struggling lately, but the selling pressure may be coming to an end soon.

GenMark Diagnostics Sees Hammer Chart Pattern: Time to Buy?

GenMark Diagnostics (GNMK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is GenMark Diagnostics (GNMK) Stock a Solid Choice Right Now?

A coronavirus diagnostic test is fueling this biotech's revenue for 2020.

Will GenMark Diagnostics' Stock Keep Rising?

CARLSBAD, Calif., May  11, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, today announced the closing of its previously announced underwritten public offering of 8,341,968 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares, at the public offering price of $9.65 per share. The aggregate gross proceeds to GenMark, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $80.5 million.

GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock,  Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Compugen

Chegg

Top Ranked Momentum Stocks to Buy for May 8th

CARLSBAD, Calif., May  06, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, today announced the pricing of its previously announced underwritten public offering of 7,253,886 shares of its common stock at a public offering price of $9.65 per share. The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $70.0 million. The offering is expected to close on or about May 11, 2020, subject to customary closing conditions.

GenMark Prices Public Offering of Common Stock

CARLSBAD, Calif., May  06, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care, announced today that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by GenMark.  GenMark intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GenMark Commences Public Offering of Common Stock

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q1 2020 Results - Earnings Call Transcript

GenMark Diagnostics (GNMK) delivered earnings and revenue surprises of 75.00% and 0.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GenMark Diagnostics (GNMK) Reports Q1 Loss, Tops Revenue Estimates

CARLSBAD, Calif., May  04, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel has been appointed President and Chief Executive Officer effective immediately. Mendel, who will also join the Board of Directors, has served as interim CEO since February 2020. 

GenMark Diagnostics Announces Scott Mendel Appointed CEO

Investors appear to have high hopes for the company's COVID-19 diagnostic test sales as states move toward reopening their economies.

Why GenMark Diagnostics  Stock Is  Soaring Today

Investors need to pay close attention to GenMark (GNMK) stock based on the movements in the options market lately.

Implied Volatility Surging for GenMark (GNMK) Stock Options

GenMark Diagnostics Inc. (NASDAQ: GNMK) shares shot up early on Wednesday after the company provided an update on its quarterly numbers and where it stands with its coronavirus test.

GenMark’s Q1 Could See a Huge Boost From COVID-19

First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth

GenMark Diagnostics Provides Preliminary Financial and Operational Results for First Quarter 2020 and Increases 2020 Revenue Guidance

CARLSBAD, Calif., March  23, 2020  (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR).

News for GenMark Diagnostics Stock (GNMK)